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As we embrace for another exciting year (2016), we are
thrilled to announce JCB has been indexed in the DOAJ
(Directory of Open Access Journals) (https://doaj.org/toc/
1849-4544)! This was attributable to the number of quality
published original research articles in 2015 with the help of
our Associate Editors and Editorial Board. We published
several papers covering each of the main topics within the
scope of the journal from cell-free DNA, circulating tumour
cells and extracellular vesicles to circulating proteins. In
addition, we opened a new technology forum presenting
the latest technology and published its first article entitled,
“Analytical Validation and Capabilities of the Epic CTC
Platform: Enrichment-Free Circulating Tumour Cell
Detection and Characterization” by Shannon Werner and
her colleagues.
Over the past year, we were proud to announce several
ongoing developments such as the expansion of our
Associate and Editorial Board with key opinion leaders in
the circulating biomarker field including: Lawrence
Rajendran (University of Zurich, Switzerland) as part of
our Associate Editors team, and Quentin Qiang Liu (Dalian
Medical University) and Shlomit Kenigsberg (CReATe
Fertility Centre, Canada) as members of our Editorial
Board.
JCB is now media partners with both SelectBio and the
Cambridge Healthtech Institute (CHI). JCB has arranged a
discount for our readers when registering for SelectBio and
CHI events, which by the way, have many presenters that
are members of our Associate Editors and Editorial Board.
Additional information about such opportunities can be
found on JCB’s news page (bit.ly/1p9EXVd).
As an ongoing partnership/collaboration with the BioPhar‐
ma Research Council (http://www.biopharmaresearch‐
council.org/), the Editor-in-Chief, Winston Patrick Kuo
organized three events around the “microbiome”, two as a
webinar series and the other, a conference hosted by the
National Cancer Institute. In the first webinar, we were able
to utilize our Editorial team to suggest the theme and
present in the first session “Introduction to the Micro‐
biome” by Alexander “Sasha” Vlassov, PhD, and as well as
other talks from Camilia Martin, MD, MS of the Harvard
Medical School, and Floyd Dewhirst, PhD, of The Forsyth
Institute. The second webinar was held as a four-session
webinar series in April 2015 entitled “Short Course in the
Microbiome”. The goal of the short course was to provide
insights at an introductory level, yet also a broad overview
of the field in the form of an exchange between researchers
from academia and industry in the clinical applications of
the oral and gut microbiome. We had world renowned
speakers including Rob Knight from UCSD, Camilia
Martin from the Harvard Medical School, and Romina
Goldszmid and K. Leigh Greathouse both from the NIH.
They covered topics related to the “system biology ap‐
proach”, “spatially explicit maps”, “microbiome and
cancer therapy” and a “round-up of the latest news”. A
meeting dispatch was published online and is available on
the Journal of Circulation Biomarker’s site (http://www.inte‐
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chopen.com/journals/journal-of-circulating-biomarkers/
short-course-in-the-microbiome). The event at the NCI was
themed “Altering the Microbiome: Can it Impact Health?”.
The purpose of this was to discuss how the host micro‐
biome may be altered and whether such approaches can
result in a positive impact on the host. We learned that the
preparation process required about six months of coordi‐
nation. We plan to continue several webinar series on
circulating tumour cells and cell-free circulating DNA later
this year.
As we strive to publish the best science in all fields of
circulating biomarkers, the Editorial team plans to focus on
additional topics such as cell-free DNA and disruptive
technologies, among others.
JCB accepts original and review articles as well as editori‐
als, perspectives, short research reports, protocols and
methods, notes to the Editor, letters to the Editor and
meeting dispatch reports. We would like to mention that
InTech have decided that JCB will not apply any article
processing charges for authors whose research papers have
been accepted for publication in Volume 5/2016. Manu‐
script processing and peer-reviewing for JCB is conducted
entirely online. The Editorial Manager facilitates the
manuscript processing time, reducing costs and providing
a better experience for our authors and reviewers. We have
received numerous positive comments on this evolving
electronic system, and we are indebted to InTech Open
Access Publisher for managing this process for us. For more
information, please visit our new manuscript submission
system at http://www.editorialmanager.com/exo/
default.asp. In addition, we are looking to expedite the
acceptance to publishing time for our authors and will
request informal opinions from our Editorial Board for
borderline cases.
As an ongoing effort, JCB will continue to work on part‐
nering with scientific societies, and academic and industry
leaders to advance the field and to allow free access to
knowledge in the circulating biomarker space. It’s our great
pleasure to thank the Editorial team and publishers who
make this possible.
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